Azitra, Inc.
No enriched coverage for $AZTR in the last 7 days.
No SEC Form 4 filings for $AZTR in the last 30 days.
See all $AZTR insider activity →Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance BRANFORD, Conn. – October 1, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on dev
Azitra Inc. (AZTR) has advanced its Phase 1/2 trial for ATR04-484, a treatment for EGFR inhibitor-associated skin rash, to Cohort 2 after positive safety data from Cohort 1. The trial will now enroll 24 patients for daily application over 28 days. ATR04-484 has FDA Fast Track designation, targeting 150,000 U.S. patients annually. The study is conducted at six sites, including MD Anderson and Yale.
Azitra, Inc. (AZTR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 28, 2026, Azitra, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which the Company may issue and sell, from time to time, t
Recent AZTR coverage spans financial news, corporate actions and market movers.
Early‑stage trial progress may lift sentiment but impact is limited until efficacy data emerge.
The advancement to Cohort 2 is a positive development that may lift the stock.
Potential dilution and modest cash inflow from a small at‑the‑market offering.
New preclinical ATR-COSF data plus updated clinical timelines (ATR-04 topline expected Q4 2026) can re-rate near-term probability of success, but cash burn remains a key overhang.
The filing adds fresh clinical and preclinical progress plus a capital-allocation change (pausing ATR-12 enrollment), which can re-rate near-term risk and timelines.
AlphAI scores every news story that mentions AZTR with an AI model for sentiment and relevance, and aggregates insider trades from Azitra, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance BRANFORD, Conn. – October 1, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on dev
1 min readAzitra Inc. (AZTR) has advanced its Phase 1/2 trial for ATR04-484, a treatment for EGFR inhibitor-associated skin rash, to Cohort 2 after positive safety data from Cohort 1. The trial will now enroll 24 patients for daily application over 28 days. ATR04-484 has FDA Fast Track designation, targeting 150,000 U.S. patients annually. The study is conducted at six sites, including MD Anderson and Yale.
2 min readAzitra, Inc. (AZTR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 28, 2026, Azitra, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which the Company may issue and sell, from time to time, t
1 min readAzitra, Inc. (NYSE American: AZTR) reported Q2 2026 results for the quarter ended June 30, 2026. R&D was $1.4 million, G&A $2.1 million, and net loss $3.3 million. Cash and cash equivalents were $6.7 million. The company cited preclinical ATR-COSF data, continued Phase 1/2 enrollment for ATR-04 EGFR inhibitor-associated rash, and plans to pause ATR-12 enrollment. Topline ATR-04 data is expected in Q4 2026.
6 min readAzitra, Inc. (AZTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates BRANFORD, Conn. – August 12, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precisio
5 min readAzitra, Inc. (NYSE American: AZTR) reported ex vivo human skin study results for its ATR-COSF filaggrin-domain supernatant. Multiple-dose testing showed increased rHDfilaggrin distribution into stratum granulosum versus prior single-dose work. A hydrogel dose range (0.0% to 7.5% w/w) increased elasticity up to 4.4-fold versus placebo, with non-irritating safety findings.
4 min readAzitra, Inc. (AZTR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001701478 0001701478 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of
2 min readAzitra, Inc. (NYSEAMER: AZTR) announced its Q1 2026 financial results, reporting increased R&D expenses and a net loss of $3.93 million, but also a significant increase in cash and stockholder's equity. The company is continuing IND-enabling studies for its product candidates and noted a substantial increase in weighted average shares outstanding, suggesting recent capital raises. Investors are advised to monitor progress on studies and capital management due to potential share price impact.
4 min readAzitra Inc. (AZTR) shares surged over 80% after the biopharmaceutical firm announced a private placement to raise more than $31 million. This rally comes days after the company received a listing warning from NYSE American LLC for failing to meet minimum stockholders' equity requirements. The funding will be used to advance new protein and peptide research programs for skincare solutions, despite the company reporting widening net losses.
4 min readAzitra Inc. AZTR shares skyrocketed 58.71% in after-hours trading to $1.51 on Thursday, following the implementation of a 1-for-6.66 reverse stock split and significant SEC filing activity that revealed new institutional ownership. Check out the current price of AZTR stock here.
3 min read
